Clinical characteristics and anti-ZSCAN1 antibody titer analysis in a nationwide survey of ROHHAD (-NET) syndrome
Abstract
This study suggests that we need to evaluate clinically and in detail the autonomic dysregulation and hypoventilation in order to diagnose ROHHAD (-NET) syndrome in its early stages. Additionally, anti-ZSCAN1 antibody titers reflect the association of neural crest tumors (NCT) and may serve as a potential marker for the efficacy of tumor therapy. We also propose the anti-ZSCAN1 antibody titer as an indicator for the clinical management of ROHHAD (-NET) syndrome.